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Abstract
Background: Approximately 25% of patients with colorectal cancer (CRC) will have liver metastases classified as
synchronous or metachronous. There is no consensus on the defining time point for synchronous/metachronous,
and the prognostic implications thereof remain unclear. The aim of the study was to assess the prognostic value of
differential detection at various defining time points in a population-based patient cohort and conduct a literature
review of the topic.
Methods: All patients diagnosed with CRC in the counties of Stockholm and Gotland, Sweden, during 2008 were
included in the study and followed for 5 years or until death to identify patients diagnosed with liver metastases.
Patients with liver metastases were followed from time of diagnosis of liver metastases for at least 5 years or until
death. Different time points defining synchronous/metachronous detection, as reported in the literature and
identified in a literature search of databases (PubMed, Embase, Cochrane library), were applied to the cohort, and
overall survival was calculated using Kaplan-Meier curves and compared with log-rank test. The influence of
synchronously or metachronously detected liver metastases on disease-free and overall survival as reported in
articles forthcoming from the literature search was also assessed.
Results: Liver metastases were diagnosed in 272/1026 patients with CRC (26.5%). No statistically significant
difference in overall survival for synchronous vs. metachronous detection at any of the defining time points (CRC
diagnosis/surgery and 3, 6 and 12 months post-diagnosis/surgery) was demonstrated for operated or non-operated
patients. In the literature search, 41 publications met the inclusion criteria. No clear pattern emerged regarding the
prognostic significance of synchronous vs. metachronous detection.
Conclusion: Synchronous vs. metachronous detection of CRC liver metastases lacks prognostic value. Using primary
tumour diagnosis/operation as standardized cut-off point to define synchronous/metachronous detection is
semantically correct. In synchronous detection, it defines a clinically relevant group of patients where individualized
multimodality treatment protocols will apply.
Keywords: Colorectal cancer, Liver metastases, Synchronous, Metachronous
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jennie.engstrand@sll.se
1Division of Surgery, Department of Clinical Sciences, Karolinska Institutet,
Danderyd Hospital, 182 88 Stockholm, Sweden
Full list of author information is available at the end of the article
Engstrand et al. World Journal of Surgical Oncology          (2019) 17:228 
https://doi.org/10.1186/s12957-019-1771-9
Background
In the USA as well as in Europe, colorectal cancer
(CRC) is the third most common cancer and a leading
cause of cancer-related death [1]. Approximately 25% of
patients diagnosed with CRC will be diagnosed with liver
metastases during the course of the disease [2–4]. A
large number of clinic-pathologic features of CRC liver
metastases (CRCLM), including patient characteristics,
pre-operative factors, primary tumour and liver metasta-
ses characteristics and operative factors have been
assessed as prognostic factors [5, 6]. Synchronous vs.
metachronous detection or occurrence of CRCLM as
prognostic factor was mainly investigated and reported
in surgical case series [7, 8]. There is, however, no con-
sensus on the definition of synchronous and metachro-
nous as used in the context of CRCLM. The time point
of diagnosis of the primary tumour, alternatively the
time of operation of the primary tumour and a variation
of time intervals related to these time points have been
used [3]. An effort to solve this was made by Adam et al.
in 2015, where synchronous was defined as liver metas-
tases detected before or at the time of diagnosis of the
primary tumour [9]. With current trends and develop-
ments in CRC and CRCLM treatment, the detection of
liver metastases at the time of diagnosis of the primary
tumour has important therapeutic implications, both in
terms of surgical strategy and the planning of oncologic
treatment [10–13]. In a previously published population-
based cohort of patients with CRC, the time of detection
of liver metastases (synchronous vs. metachronous) did
not significantly influence survival in a multivariate ana-
lysis [4]. In this study, previously used definitions of syn-
chronous vs. metachronous detection of CRCLM are
applied on that same patient cohort to assess the prog-
nostic value of detection at the various defining time
points in a population-based cohort. To identify previ-
ously used definitions for synchronous vs. metachronous
detection of CRCLM, a literature search was performed
for articles where a time point was specified for syn-
chronous vs. metachronous detection.
Methods
To assess the potential prognostic impact of detection of
liver metastases at various time points used to define
synchronous vs. metachronous detection of CRCLM, a
population-based patient cohort was used. All patients
that were diagnosed with CRC in the Swedish counties
of Stockholm and Gotland between 1 January 2008 and
31 December 2008 (total population as of 1 November
2008 = 2,034,886) were identified in the Swedish Colo-
rectal Cancer Registry (SCRCR) and included in the
study. The SCRCR is a validated database covering more
than 99% of colon cancers diagnosed in Sweden between
2007 and 2011 [14]. Data regarding metastatic disease is
not registered in the SCRCR and in order to identify pa-
tients in whom liver metastases were detected, the elec-
tronic patient records of all included in the study were
reviewed for at least 5 years after time of diagnosis of the
primary tumour, or until time of death. The authors
reviewed all imaging findings and notifications of intra-
operative detection of metastases and documented the
occurrence of any metastatic disease. Specifically, the
time points for diagnosis of the primary tumour, surgery
for the primary tumour, diagnosis of liver metastases
and in deceased patients’ time of death were docu-
mented. A detailed description of the data collection and
demographic and clinic-pathological features of all in-
cluded patients has been published elsewhere [4]. In that
paper, a slightly different definition of synchronous vs.
metachronous was used with some liver metastases de-
tected after treatment allocation but during neoadjuvant
chemotherapy were categorized as synchronous. The
overall survival (OS) of patients with synchronously vs.
metachronously detected liver metastases was compared
for different time points defining synchronous vs. meta-
chronous detection, identified from the literature search
as described below. The calculation was performed for
the group of patients with liver metastases as a whole, as
well as separately for patients undergoing curative-
intended liver intervention (resection and/or local abla-
tion) and those treated with palliative intent. OS was es-
timated from time of diagnosis of liver metastasis to
death, last follow-up or censored January 21, 2019.
In order to define previously used time point defini-
tions of synchronous vs. metachronous detection, a lit-
erature search was performed for publications between
2005 and 2018 that described definitions of synchronous
vs. metachronous detection. The reported prognostic
value of the distinction in articles where OS and/or
disease-free survival (DFS) were reported was also docu-
mented. The PubMed, Embase and the Cochrane library
databases were searched, and articles were reviewed fol-
lowing the PRISMA statement guidelines [15]. The fol-
lowing search headings were used: (CRC OR colorectal
cancer) AND (liver OR hepatic) AND (metastases OR
metastasis OR metastatic) AND (synchronous OR meta-
chronous) AND survival. Articles not written in English,
duplicates, conference abstracts, case reports, review ar-
ticles and articles written before 2005 were excluded.
The remaining articles were subjected to a more thor-
ough screening. For inclusion, the studies had to (a) spe-
cify a definition of synchronous vs. metachronous
detection of CRCLM and (b) assess synchronous vs.
metachronous detection as a prognostic factor (as OS
and/or DSF). If the same population was used in two dif-
ferent studies, the later study was included. Publications
not meeting the inclusion criteria were deemed irrele-
vant. A reference screening was performed to detect
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possible missed articles. The study was approved by the
Regional Ethical Review Board in Stockholm.
Statistical analysis
Non-normally distributed continuous data are presented
as medians (min, max) and categorical data as frequen-
cies (percentage). Survival curves were calculated using
Kaplan-Meier estimates, and survivor functions were
compared using the log-rank test. The threshold for stat-
istical significance was set to a < 0.05. Sigmaplot 13
(Systat Software, San Jose, CA 95131, USA) were used
for the statistical analyses.
Results
Survival data from the population-based cohort
During the study period, a total of 1026 patients were di-
agnosed with CRC. The median age was 71 years (31, 97),
485 (47.3%) were females and 651 (65.1%) had a primary
tumour of left-sided origin. At 5-year follow-up, 272
(26.5%) of subjects (57.7% male and 42.3% female) had
been diagnosed with liver metastases of whom 65 (24%)
had undergone liver resection, Table 1. The cumulative
incidence of detection of the liver metastases as related to
the time of diagnosis of the primary tumour are depicted
in Fig. 1. The number of patients with metastases that
were classified as synchronous or metachronous according
to the different time points used in the literature, namely
the time of primary tumour diagnosis (in non-operated
patients) or time of primary tumour surgery (operated pa-
tients) and 3, 6 and 12months after the primary tumour
diagnosis/surgery, is shown in Table 2.
The overall survival curves of patients with synchron-
ously and metachronously detected metastases for oper-
ated and non-operated patients are shown for the
different synchronous vs. metachronous-defining time
points (Fig. 2). No statistically significant difference in
survival at any of the time points was seen, neither for
operated nor for non-operated patients.
Review of existing literature on the topic
The flow chart presenting the results of the electronic
database search is shown in Fig. 3. After exclusion, 39
articles were retained, and 2 articles were added from
reference screening. The majority of studies reported pa-
tients only operated for CRCLM (n = 34), 6 included
both operated and non-operated patients and 1 study
only included patients treated with palliative intent
(Table 3). Prognostic results as per time point are sum-
marized in Table 4. There was a considerable variation
in the number of subjects included in studies (minimum
40, maximum 1784), and the proportion of patients with
synchronous detection of liver metastases varied from
31.3 to 79.7%. The most commonly used defining time
point for synchronicity was at primary tumour
diagnosis/surgery (18 out of 41 publications). There was
a trend in a better OS of metachronous detected metas-
tases with an earlier cut-off with 50% of studies showing
statistically significant differences when using a 0- or 3-
month definition, compared to 33% with a 6-month def-
inition and 0% for a 12-month definition; the majority of
the studies concluded a non-significant prognostic value
of synchronous vs. metachronous detection.
Discussion
The present study questions the prognostic impact of
the time of liver metastases detection in CRC and also
Table 1 Patient and tumour characteristics of 272 patients with
liver metastases
n = 272
Gender, male/female (%) 157/115 (57.7/42.3)
Age, years (min, max) 68 (31, 95)
Primary tumour location, n (%)
Caecum/ascending colon 64 (23.5)
Transverse colon 13 (4.8)
Descending/sigmoid colon 90 (33.1)
Rectum 95 (34.9)
Multiple primary tumours 9 (3.3)
Unknown 1 (0.4)
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Size of largest liver metastasis (mm) (min, max) 26 (5, 120)
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the meaningfulness of time points other than the time of
primary tumour diagnosis in non-operated patients and
time of primary tumour surgery in operated patients as
definition of synchronous detection. In a well-defined
cohort from a well-defined geographical region in
Sweden, no significant difference was seen in survival as
measured from time of detection of liver metastases to
death between the two groups, irrespective of time
points being used.
In patients with CRCLM, the proportions of tumours
being detected synchronously and metachronously and
the prognostic value of this distinction have been re-
ported in numerous studies [3, 9]. Reports addressing
the issue differ considerably regarding the time points
used as cut-off for defining synchronous vs. metachro-
nous detection. Furthermore, there are wide variations
in the number of subjects and the proportions of syn-
chronous vs. metachronous detection in the included co-
horts. Although a trend was seen in patients with
metachronous detection having a better OS with early
time points as cut-off (50% of studies showing statisti-
cally significant differences using a 0- or 3-month defin-
ition) as opposed to later time points (50% for a 6-
month and 0% for a 12-month definition), there is no
compelling evidence that the distinction has any
prognostic value. In a study by Furukawa et al., the prog-
nostic value of synchronous vs. metachronous detection
was investigated in a cohort of patients with unresect-
able liver metastases. With the cut-off defined as the
time of primary tumour evaluation, no difference in the
OS of patients was found [33]. Adam et al. took a con-
sensus approach to the same question and concluded
that metachronous tumours are regarded as having a
better biology and better survival, and the conclusion
was illustrated with survival curves from LiverMetSurvey
[9].
With current trends and developments in CRC and
CRCLM treatment, establishing the presence of liver
metastases at the time of diagnosis of the primary
tumour has important therapeutic implications [6, 55].
Firstly, surgical intervention for the CRCLM needs to be
coordinated with the surgery for the primary tumour.
Different surgical options, for example the liver first ap-
proach or simultaneous resection of primary tumour
and liver metastases, need to be considered [10, 56–58].
Secondly, it may also influence the use and timing of on-
cologic treatment, with neoadjuvant chemotherapy in-
creasingly being favoured in patients with liver
metastases detected before surgery of the primary
tumour [11–13].
Fig. 1 The time of detection of the liver metastases as related to the time of detection of the primary tumour (non-operated, palliative)/operation
for the primary tumour (resected)
Table 2 The number of patients with liver metastases classified as synchronous vs. metachronous according to the different
defining time points.
Time point Synchronous Metachronous
Total Resected Non-resected Total Resected Non-resected
Primary tumour diagnosis/surgery 155 26 129 117 39 78
Three months post-primary tumour diagnosis/surgery 174 29 145 98 36 62
Six months post-primary tumour diagnosis/surgery 186 34 152 86 31 55
Twelve months post-primary tumour diagnosis/surgery 207 39 168 65 26 39
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Terminology frequently used in the literature, for ex-
ample development of synchronous vs. metachronous
metastases, implies two different clinical entities, creat-
ing the unfounded impression that the metastatic events
occur during the respective periods. The mechanism for
CRC metastases to the liver has been described in detail,
with tumour cells entering the liver either via the portal
vein or hepatic artery, the common point of entry being
the sinusoidal space [59]. Whether the risk for new me-
tastases to the liver ceases at removal of the primary
tumour is unclear. Patterns of hepatic recurrence ob-
served in a cohort of patients transplanted for CRCLM
suggest that previously undiagnosed lung or lymph node
metastases could be the source of liver metastases in the
transplanted liver [60, 61]. The development of liver me-
tastases in the transplanted liver in the absence of any
Fig. 2 a–d Overall survival curves for synchronous and metachronous detected metastases. Operated and non-operated patients shown for the
different synchronous/metachronous cut-off points at a, detection of the primary tumour (non-operated, palliative)/operation for the primary
tumour (resected) and b, 3 months, c, 6 months and d, 12 months after detection/resection of the primary tumour
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other metastases suggests that viable tumour cells may
persist in the circulation after elimination of the primary
tumour and resection of the whole liver with liver me-
tastases. It is however more plausible that pre-
operatively present but undetected hepatic lesions ac-
count for the vast majority of liver metastases detected
after operation of the primary tumour. These lesions are
therefore potentially detectable at initial liver work-up.
In the light of the above-mentioned, we propose a
standardized definition for synchronous vs. metachro-
nous detection of CRCLM that will be rational, seman-
tically correct and will have a clear clinical application,
namely the time of operation for the primary tumour in
operated patients and the time of diagnosis of the pri-
mary tumour, including the metastatic work-up, for pa-
tients treated non-operatively for the primary tumour as
cut-off. The rationale for having the cut-off for syn-
chronicity during and not before the primary tumour
operation is that, even though establishing the presence
of metastases during the pre-operative work-up of the
primary tumour is optimal in terms of treatment plan-
ning, intra-operative detection still to some extent offers
the possibility of changing the treatment plan if needed.
Intra-operative detection of pre-operatively undiagnosed
liver metastases is fortunately an increasingly rare event
due to high-quality imaging using high-end technology
and state-of-the-art protocols during work-up [62]. The
proposed definition will also focus attention on the ef-
fectiveness of hepatic imaging at the time of detection of
the primary tumour, the proportion of metastases de-
tected before operation for the primary tumour being
directly related to the quality and diligence of the im-
aging strategy. This could serve as a robust parameter of
pre-operative imaging quality control. A randomized
trial has shown that MRI with liver-specific contrast
is superior for detection of CRCLM, as compared to
contrast-enhanced CT and MRI with extracellular
contrast [63]. Health economic studies suggest that
an MRI first approach is from a cost perspective
comparable to a step-up approach with contrast-
enhanced CT first [64, 65].
There are, however, a number of limitations that need
to be considered in the interpretation and generalization
of results. The SCRCR only includes the Swedish popu-
lation, a relatively homogeneous group in terms of eth-
nic diversity, and results may not be generalizable. In a
previous publication on the total CRC patient cohort
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Fig. 3 The flow chart presenting the results of the electronic database search
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Table 3 Studies comparing the prognostic value of synchronous vs. metachronous detection of CRCLM published in 2005–2018
Reference Year of publication Cohort Definition* Synchronous/metachronous OS DFS
Mutsaerts et al. [16] 2005 Operated 2 43/59 S (p = 0.048) NR
Leporrier et al. [17] 2006 All 3 250/108 NS (p = 0.498) NR
Minagawa et al. [18] 2006 Operated 1 187/182 NS (p = 0.19) NR
Taniai et al. [19] 2006 Operated 4 67/41 NS (p = 0.354) NR
Shimizu et al. [20] 2007 Operated 3 70/94 NS (p = 0.738) NR
Tsai et al. [21] 2007 Operated 1 97/58 NS (p = 0.150) S (p = 0.004)
Wang et al. [22] 2007 Operated 3 514/409 NS (p = 0.312) NR
Bockhorn et al. [23] 2008 Operated 4 101/101 NS (p = 0.78) NS (p = 0.28)
Hamady et al. [24] 2008 Operated 4 138/46 NS (p = 0.6) NR
Vigano et al. [25] 2008 Operated 1 55/66 S (p = 0.011) NR
Konopke et al. [26] 2009 Operated 1 70/131 S (p = 0.030) NR
Ng et al. [27] 2009 Operated 2 35/20 NS (p = 0.075) NS (p = 0.43)
Xu et al. [28] 2009 Operated 3 379/290 NS (p > 0.05) NR
Tonelli et al. [29] 2010 Operated 1 70/37 S (p = 0.018) NR
Van der Pool et al. [30] 2010 Operated 1 105/167 NS (p = 0.6) NS (p = 0.3)
Brouquet et al. [31] 2011 Operated 1 47/13 S (p = 0.003) NR
Settmacher et al. [7] 2011 Operated 1 158/224 S (p = 0.033) S (p = 0.003)
Swan et al. [32] 2011 Operated 4 577/625 NS (p = 0.530) NR
Furukawa et al. [33] 2012 Unresectable 1 26/14 NS (p = 0.085) NA
Vigano et al. [34] 2012 Operated 1 182/194 NS NR
Dexiang et al. [35] 2012 All 3 1061/552 S (p < 0.001) NR
Gur et al. [36] 2013 Operated 1 79/79 NS (p = 0.14) S (p = 0.04)
Nanji et al. [37] 2013 Operated 1 125/195 S (p = 0.003) NS (p = 0.092)
Ribeiro et al. [38] 2012 Operated 3 89/81 NS (p = 0.162) NS (p = 0.214)
John et al. [39] 2013 Operated 4 257/174 NS (p = 0.253) NR
Hackl et al. [3] 2014 All 2 1019/407 NS (p = 0.799) NR
Kumar et al. [40] 2014 All 1 1054/542 S (p = 0.003) NR
Kuo et al. [41] 2015 Operated 2 104/55 S (p = 0.001) NR
Ali et al. [42] 2015 Operated 3 66/50 NS (p = 0.997) NR
Kawamura et al. [43] 2016 Operated 1 34/38 S (p = 0.010 NS
Lemke et al. [44] 2016 Operated 3 68/84 S (p = NR) NR
Miller et al. [45] 2017 Operated 3 181/46 NS (p = 0.58) NS (p = 0.87)
Angelsen et al. [46] 2017 Operated 4 39/488 NS (p = 0.068) NR
Bartolini et al. [47] 2018 Operated 1 39/31 NS (p = 0.085) S (p = 0.0001)
Margonis et al. [48] 2018 Operated 3 266/583 S (p = 0.02) NS (p = 0.58)
Marques et al. [49] 2018 Operated 3 95/55 NS (p = 0.505) NS (p = 0.07)
Memeo et al. [50] 2018 Operated 4 753/1031 NS (p = NR) NR
Quireze et al. [51] 2018 All 3 38/16 S (0.036) metachronous worse NS (p = 0.629)
Suthananthan et al. [52] 2018 All 1 276/98 NS (p = 0.172) NR
Strandberg et al. [53] 2018 Operated 1 146/138 S (p = 0.031) NR
Zhao et al. [54] 2018 Operated 1 172/71 NS (p = 0.110) NS (p = 0.088)
*Definition: 1, Time of primary tumour diagnosis/operation; 2, 3 months after primary tumour diagnosis/operation; 3, 6 months after primary tumour diagnosis/
operation; 4, 12 months after primary tumour diagnosis/operation. NA not applicable, NR not reported, S significant, NS non-significant, OS overall survival, DFS
disease-free survival
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study, a Cox regression analysis, including age, sex,
tumour factors (tumour stage, nodal stage, right- vs. left-
sided), number and size of liver metastases, time of de-
tection (synchronous vs. metachronous), liver resection
and the presence of lung metastases, was performed. In
the multivariate analysis age, primary tumour origin
(midgut vs. hindgut), size of largest liver metastasis and
liver resection significantly predicted survival, while syn-
chronous vs. metachronous (HR 0.91, 95% CI 0.64–1.30)
did not significantly influence survival [4]. In this article,
patients that were operated and patients not operated
for CRCLM were assessed separately. Ideally, additional
treatment such as neoadjuvant, adjuvant and palliative
chemotherapy therapy should have been controlled for
in a multivariable analysis, but the rather small CRCLM
cohort precludes further subgroup analysis.
Although the PRISMA statement guidelines were ad-
hered for extraction of published data required for the
study (definitions for and impact of synchronous vs.
metachronous detection on prognosis at the different
time points), a formal systematic review was not per-
formed. A systematic review and meta-analysis to assess
the prognostic value of synchronous vs. metachronous
detection using the proposed definition is highly desir-
able, as this may clarify the impact on prognosis.
Conclusion
This study, to our knowledge, is the first to address the
issue in a well-validated population-based cohort, and it
fails to show any prognostic value in distinguishing syn-
chronous from metachronous detection of CRCLM for
any of the previously reported defining cut-off points,
neither for operated patients nor for patients treated
with palliative intent. We suggest using primary tumour
diagnosis/operation as standard cut-off point to define
synchronous/metachronous detection as a clinically rele-
vant definition.
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